Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Staar warning letter progress

This article was originally published in The Gray Sheet

Executive Summary

Staar Surgical is preparing for facility inspections following FDA's recent pronouncement that the firm's warning letter corrective action plan is "adequate," the company says. The Dec. 22 warning letter stemmed from quality system regulation and device reporting violations discovered during a pre-approval inspection related to Staar's Collamer implantable contact lens (1"The Gray Sheet" Jan. 12, 2004, p. 7). Staar will provide an update on the expected re-inspection timeframe by the end of April. The firm's stock rose 21% March 31 on disclosure of the development...

You may also be interested in...



Staar Warning Letter Presents Challenges For ICL Approval Timeline

Staar Surgical continues to anticipate approval for the Collamer ICL implantable contact lens by April, despite compliance issues raised in a Dec. 22 FDA warning letter

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel